Traverse Biotech, Inc

Traverse harnesses clinically validated technologies to make the immune system part of the cure. We are developing the next generation of first-in-class immunotherapies. Each pipeline product that Traverse acquires is based on a clinically validated platform in an original risk-sharing model with the licensing partner thereby leveraging technical and developmental expertise. Our lead product is a T-cell engaging bispecific antibody that overcomes the immunosuppressive tumor microenvironment in difficult-to-treat solid cancers.